|
**Overview**: Galactosemia 3 Panel**Introduction**: The Galactosemia 3 Panel is a diagnostic tool designed for comprehensive galactosemia screening using whole blood samples. In India, comprehensive testing for GALT, GALE, GALK1 mutations and galactose levels identifies classical, Duarte, and variant forms, crucial in neonates with sepsis or jaundice. High morbidity from underdiagnosis in rural/low-SES settings, limited advanced genetic testing, delayed dietary intervention leading to irreversible damage. Per molecular pathology practices aligned with ICMR guidelines, the test employs PCR for mutations and galactose measurement over 1-2 days with high accuracy, valuable for full diagnostic workup. This diagnostic falls under genetic disorder screening and targets symptomatic neonates or high-risk families, addressing accurate detection to guide lactose-free diet and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise comprehensive diagnosis and reducing complications. Its whole blood-based approach ensures reliable multi-parameter analysis.**Other Names**: Galacto 3 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Comprehensive galactosemia panel; in India, expanding in metabolic screening.**Purpose**: The test assesses 4 parameters including GALT mutation to guide comprehensive galactosemia screening, detect variants, inform management.**Test Parameters**: 1. GALT Mutation, 2. GALE Mutation, 3. GALK1 Mutation, 4. Galactose Levels.**Pretest Condition**: No fasting required; patients should be symptomatic neonates.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on jaundice, vomiting, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated galactosemia including damage, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and biochemical assay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or recent milk exposure can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Pathogenic variants/elevated galactose confirm galactosemia, necessitating specialist input.**Specialist Consultation**: Pediatricians or geneticists should be consulted for management.**Additional Supporting Tests**: Urine reducing substances, enzyme activity for confirmation.**Test Limitations**: May miss ultra-rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
